Shopping Cart
- Remove All
Your shopping cart is currently empty
STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies.


| Description | STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies. |
| In vitro | STL001, in concentrations ranging from 1-10 μM over 24 hours, causes a dose-dependent reduction in cellular FOXM1 protein levels. At 5 μM for 24 hours, STL001 prompts the translocation of nuclear FOXM1 to the cytoplasm, enhancing its autophagic degradation. In U2OS-C3-luc cells, treatment with 5 μM for 24 hours resulted in decreased FOXM1 levels and elevated expression of the autophagy marker protein LC3. |
| Molecular Weight | 509.52 |
| Formula | C27H23N7O4 |
| Cas No. | 3047493-70-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.